

POLICY TITLE	NONCONTRACEPTIVE USE OF INTRAUTERINE DEVICES (IUDs)
POLICY NUMBER	MP-7.026

Original Issue Date (Created):	2/7/2005
Most Recent Review Date (Revised):	8/27/2018
Effective Date:	8/27/2018

[POLICY RATIONALE](#)  
[DISCLAIMER](#)  
[POLICY HISTORY](#)

[PRODUCT VARIATIONS](#)  
[DEFINITIONS](#)  
[CODING INFORMATION](#)

[DESCRIPTION/BACKGROUND](#)  
[BENEFIT VARIATIONS](#)  
[REFERENCES](#)

## I. POLICY

**NOTE: For the use of intrauterine devices for contraceptive purposes - refer to the Certificate of Coverage and Preventive Benefits.**

Intrauterine devices (IUDs) may be **medically necessary** for non-contraceptive uses for the following indications:

- As indicated by the Food and Drug (FDA) label information, use of levonorgestrel intrauterine systems (LNG IUS) devices containing 52 mg levonorgestrel (Mirena®) may be considered **medically necessary** to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention.
- Off-label use of levonorgestrel intrauterine systems (LNG IUS) devices containing 52 mg levonorgestrel (Mirena®) for conditions other than specified in the FDA label information above may be considered **medically necessary** for the following.
  - As an alternative to other hormonal regimens (oral contraceptives, cyclic or continuous progestins, etc.) or as a treatment option to surgical interventions in an individual who has excessive or irregular bleeding defined as one of the following:
    - Idiopathic menorrhagia: excessively heavy, regular menses in the absence of intracavitary pathology or coagulopathy OR
    - Menometrorrhagia: bleeding that is excessive in amount, is prolonged in duration, and may occur at regular or irregular intervals.
  - As an alternative delivery system to protect against endometrial hyperplasia in women who are currently receiving selective estrogen receptor modulators.
  - Management of recurrent pelvic pain secondary to multi-treated endometriosis.

Levonorgestrel intrauterine systems (LNG IUS) devices containing less than 52 mg levonorgestrel (Skyla™, Kyleena™) for off-label non-contraceptive use are considered **investigational**. There is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

<b>POLICY TITLE</b>	<b>NONCONTRACEPTIVE USE OF INTRAUTERINE DEVICES (IUDs)</b>
<b>POLICY NUMBER</b>	<b>MP-7.026</b>

The noncontraceptive use of IUDs for indications other than those described in the policy criteria are considered **investigational** as there is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

Removal of an intrauterine device (IUD) for medical conditions such as unexplained abnormal uterine bleeding or pregnancy may be considered **medically necessary**.

*Cross-references:*

**MP-2.103** Off Label Use of Medications

**MP-7.013** Endometrial Ablation

**II. PRODUCT VARIATIONS**

[TOP](#)

This policy is applicable to all programs and products administered by Capital BlueCross unless otherwise indicated below.

**III. DESCRIPTION/BACKGROUND**

[TOP](#)

Intrauterine devices (IUDs) are devices that are inserted in the uterus to prevent effective conception. IUDs can be classified as non-hormonal (e.g. ParaGard® copper IUD) or hormonal (e.g. Mirena® levonorgestrel intrauterine systems [LNG IUS] or Skyla™ levonorgestrel-releasing intrauterine system).

The Mirena® LNG IUS device received U. S. Food and Drug Administration (FDA) approval in December 2000 for intrauterine contraceptive use for up to five years. On October 1, 2009, the FDA approved the Mirena® (levonorgestrel intrauterine system 52 mg) to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention.

The major advantage of this IUD is that it is progestin-only, avoiding estrogen contraindications. The use of LNG IUS devices for dysfunctional uterine bleeding may allow women to avoid more invasive procedures such as hysterectomy or endometrial ablation.

January 9, 2013 the U.S. Food and Drug Administration (FDA) approved Skyla™ (levonorgestrel-releasing intrauterine system) 13.5 mg, a hormone-releasing system that is placed in the uterus for the prevention of pregnancy for up to three years. No studies have been completed for the use of Skyla™ for the treatment of heavy menstrual bleeding.

February 27, 2015 the U.S. Food and Drug Administration (FDA) approved Liletta® (levonorgestrel-releasing intrauterine system) 52 mg, a hormone-releasing system to prevent pregnancy for up to 4 years. No studies have been completed for the use of Liletta® for the treatment of heavy menstrual bleeding.

POLICY TITLE	NONCONTRACEPTIVE USE OF INTRAUTERINE DEVICES (IUDs)
POLICY NUMBER	MP-7.026

**IV. RATIONALE**

[TOP](#)

For information on clinical studies for Mirena® LNG IUS, refer to the Prescribing Information.

**V. DEFINITIONS**

[TOP](#)

**DYSFUNCTIONAL UTERINE BLEEDING (DUB)** is abnormal bleeding from the uterus not caused by tumor, inflammation or pregnancy.

**MENORRHAGIA** is excessive uterine bleeding occurring at the regular intervals of menstruation, the period of flow being of greater than usual duration.

**OFF-LABEL USE** is the use of a prescription drug or medical device in the treatment of an illness or injury for which it has not been specifically approved by the FDA.

**VI. BENEFIT VARIATIONS**

[TOP](#)

The existence of this medical policy does not mean that this service is a covered benefit under the member's contract. Benefit determinations should be based in all cases on the applicable contract language. Medical policies do not constitute a description of benefits. A member's individual or group customer benefits govern which services are covered, which are excluded, and which are subject to benefit limits and which require preauthorization. Members and providers should consult the member's benefit information or contact Capital BlueCross for benefit information.

**VII. DISCLAIMER**

[TOP](#)

*Capital BlueCross medical policies are developed to assist in administering a member's benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. Capital BlueCross considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.*

<b>POLICY TITLE</b>	<b>NONCONTRACEPTIVE USE OF INTRAUTERINE DEVICES (IUDs)</b>
<b>POLICY NUMBER</b>	<b>MP-7.026</b>

**VIII. CODING INFORMATION**

[TOP](#)

**Note:** This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

**Investigational; therefore, not covered when used for any indication other than contraception:**

<b>HCPCS Code</b>	<b>Description</b>
J7296	Levonorgestrel-releasing intrauterine contraceptive system (Kyleena), 19.5 mg
J7301	Levonorgestrel-Releasing Intrauterine Contraceptive System (Skyla), 13.5 mg

**Covered when medically necessary:**

<b>CPT Codes®</b>							
58300	58301						

Current Procedural Terminology (CPT) copyrighted by American Medical Association. All Rights Reserved

<b>HCPCS Code</b>	<b>Description</b>
J7297	Levonorgestrel-releasing intrauterine contraceptive system (Liletta), 52 mg
J7298	Levonorgestrel-releasing intrauterine contraceptive system (Mirena), 52 mg
S4981	Insertion of levonorgestrel-releasing intrauterine system

<b>ICD-10-CM Diagnosis Codes</b>	<b>Description</b>
N80.0	Endometriosis of uterus
N80.1	Endometriosis of ovary
N80.2	Endometriosis of fallopian tube
N80.3	Endometriosis of pelvic peritoneum
N80.4	Endometriosis of rectovaginal septum and vagina
N92.0	Excessive and frequent menstruation with regular cycle
N92.1	Excessive and frequent menstruation with irregular cycle
N92.4	Excessive bleeding in the premenopausal period
Z30.430	Encounter for insertion of intrauterine contraceptive device
Z30.431	Encounter for routine checking of intrauterine contraceptive device
Z30.432	Encounter for removal of intrauterine contraceptive device
Z30.433	Encounter for removal and reinsertion of intrauterine contraceptive device

POLICY TITLE	NONCONTRACEPTIVE USE OF INTRAUTERINE DEVICES (IUDs)
POLICY NUMBER	MP-7.026

## IX. REFERENCES

[TOP](#)

- Abou-Setta AM, Al-Inany HG, Farquhar CM. Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery. *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.: CD005072. DOI: 10.1002/14651858.CD005072.pub2.
- American College of Obstetricians and Gynecologists ACOG committee opinion. No. 337: Noncontraceptive uses of the levonorgestrel intrauterine system. *Obstet Gynecol* 2006; 107(6): 1479-82.
- American College of Obstetricians and Gynecologists (ACOG). Intrauterine device. *Practice Bulletin* #59. January: 2005. (Reaffirmed: 2007).
- Apgar BS, Kaufman AH, George-Nwogu U, Kittendorf A. Treatment of menorrhagia. *Am Fam Physician*. 2007 Jun 15; 75(12): 1813-9.
- Bahamondes L, Petta CA, Fernandes A, Monteiro I. Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea. *Contraception*. 2007 Jun; 75(6 Suppl): S134-9. Epub 2007 Feb 16.
- Bayer Healthcare Pharmaceuticals. Mirena® Physician Information. Revised 06/2017. [Website]: <http://hcp.mirena-us.com/index.php>. Accessed June 8, 2018.
- Bayer Healthcare Pharmaceuticals. Skyla™ Healthcare Providers. Revised 03/2018. [Website]: <http://hcp.skyla-us.com/index.php#isi>. Accessed June 8, 2018.
- Behera M. Abnormal (Dysfunctional) Uterine Bleeding. *eMedicine*. Updated October 27, 2017. [Website]: <http://www.emedicine.com/med/topic2353.htm>. Accessed June 8, 2018.
- Conzen S, Matthew E. Mechanisms of action of selective estrogen receptor modulators. In: *UpToDate Online Journal* [serial online]. Waltham, MA: UpToDate; updated December 21, 2015. [Website]: [www.uptodate.com](http://www.uptodate.com). Last accessed August 17, 2016.
- Giuntoli R, Zacur H. Management of Endometrial Hyperplasia. In: *UpToDate Online Journal* [serial online]. Waltham, MA: UpToDate; updated October 7, 2014. [Website]: [www.uptodate.com](http://www.uptodate.com). Accessed July 18, 2017.
- Johnson BA. Insertion and removal of intrauterine devices. *Am Fam Physician* 2005; 71(1): 95-102.
- Lethaby AE, Cooke I, Rees M. Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding. *Cochrane Database Syst Rev* 2005; (4): CD002126.
- Levonorgestrel. In: DRUGDEX® Evaluations (Micromedex 2.0). Greenwood Village, CO: Truven Health Analytics; 2012-2013. Website: <http://www.micromedexsolutions.com/home/dispatch>. Accessed June 8, 2018.
- Reid, PC, Virtanen-Kari, S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis

<b>POLICY TITLE</b>	<b>NONCONTRACEPTIVE USE OF INTRAUTERINE DEVICES (IUDs)</b>
<b>POLICY NUMBER</b>	<b>MP-7.026</b>

*using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG 2005; 112:1121.*

*Schaedel, ZE, Dolan, G, Powell, MC. The use of the levonorgestrel-releasing intrauterine system in the management of menorrhagia in women with hemostatic disorders. Am J Obstet Gynecol 2005; 193:1361.*

*Shaw RW, Symonds IM, Tamizian O, Chaplain J, Mukhopadhyay S. Randomised comparative trial of thermal balloon ablation and levonorgestrel intrauterine system in patients with idiopathic menorrhagia. Aust N Z J Obstet Gynaecol. 2007 Aug; 47(4): 335-40.*

**X. POLICY HISTORY**

[Top](#)

<b>MP 7.026</b>	<b>CAC 10/26/04</b>
	<b>CAC 10/25/05</b>
	<b>CAC 9/26/06</b>
	<b>CAC 1/30/07</b>
	<b>CAC 2/27/07</b>
	<b>CAC 5/27/08</b>
	<b>CAC 5/26/09</b>
	<b>CAC 5/25/10</b> Consensus
	<b>CAC 4/26/11</b> Consensus
	<b>CAC 6/4/13</b> Major review. No changes to policy statements. Retirement recommended.
	<b>CAC 11/26/13</b> Minor review. Policy was not retired. Added information related to Skyla™. Also, added medically necessary policy statement for use of levonorgestrel releasing IUD 52 mg in the treatment of idiopathic menorrhagia, menometrorrhagia, protection against endometrial hyperplasia in women who are currently receiving selective estrogen receptor modulators and for management of recurrent pelvic pain secondary to multi-treated endometriosis. Added the statement “Levonorgestrel intrauterine systems (LNG IUS) devices containing less than 52 mg levonorgestrel (Skyla™) for off-label non-contraceptive use are considered <b>investigational</b> .” Deleted the following statement “The use of IUDs for contraception is generally non-covered. Individual plan contracts may allow coverage”. Deleted Medicare and Sr. Blue variations – benefits address coverage. New 2014 code added.
	<b>09/26/2014-</b> Admin coding review. Added diagnosis 617.0-617.4.
	<b>CAC 11/25/14.</b> Consensus review. No change to policy statements. References updated. Coding reviewed 11/07/2014
<b>CAC 11/24/15</b> Consensus review. No change to the policy statements. References updated. Coding reviewed.	

<b>POLICY TITLE</b>	<b>NONCONTRACEPTIVE USE OF INTRAUTERINE DEVICES (IUDs)</b>
<b>POLICY NUMBER</b>	<b>MP-7.026</b>

<p><b>Administrative 1/15/16:</b> New 2016 codes J7297 &amp; J7298 added; removed end dated code J7302.</p>
<p><b>CAC 9/27/2016:</b> Consensus review. No change to the policy statements. References updated. Coding reviewed. Variation section reformatted.</p>
<p><b>Admin Update 1/1/17:</b> New diagnosis codes added effective 10/1/16</p>
<p><b>Administrative Update 7/3/17:</b> New code (Q9984) for Kyleena™ 19.5mg added; effective 7/1/17.</p>
<p><b>CAC 9/26/17</b> Consensus review. Policy statements unchanged. References updated. Coding reviewed.</p>
<p><b>Admin Update 1/1/18:</b> Added new code J7296 and removed end dated code Q9984; effective 1/1/18.</p>
<p><b>6/8/18</b> Consensus review. No changes to the policy statements. Background revised to address Liletta® (levonorgestrel-releasing intrauterine system) 52 mg. References updated. Rationale revised to refer to the prescribing information for clinical studies.</p>
<p><b>Admin Update 8/27/18</b> A note was added to the policy for clarification which states: For the use of intrauterine devices for contraceptive purposes - refer to the Certificate of Coverage and Preventive Benefits.</p>

[Top](#)

*Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies.*